<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="364281">
  <stage>Registered</stage>
  <submitdate>16/05/2014</submitdate>
  <approvaldate>20/05/2014</approvaldate>
  <actrnumber>ACTRN12614000532606</actrnumber>
  <trial_identification>
    <studytitle>Repair of Symptomatic Ear Drum Perforations: A Pilot Study Using Celgro Trademark Type I/III Collagen Bioscaffold</studytitle>
    <scientifictitle>Repair of Symptomatic Ear Drum Perforations: A Pilot Study Using Celgro Trademark Type I/III Collagen Bioscaffold</scientifictitle>
    <utrn>U1111-1143-2851 </utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>chronic tympanic membrane perforations</healthcondition>
    <conditioncode>
      <conditioncode1>Ear</conditioncode1>
      <conditioncode2>Other ear disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Celgro Trademark Type I/III Collagen Bioscaffold.

The Type I/III Collagen Bioscaffold is circumferentially grafted onto the tympanic membrane perforation edge.

The procedure is expected to take approximately 15 minutes and it undertaken on a single occasion only.

Participants receive a local anaesthetic for this procedure. </interventions>
    <comparator>N/A</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Devices</interventioncode>
    <interventioncode>Treatment: Surgery</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Tympanic membrane wound healing will be assessed visually recording colour, transparency, blood vessels and perforation size. Photodocumentation will be used. </outcome>
      <timepoint>Every week for the first month then at 3, 6 and 12 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Hearing outcomes will be measured by an audiology assessment that measures Frequency Threshold, Pure Tone Average and Air-Bone Gap. </outcome>
      <timepoint>Every week for the first month then at 3, 6 and 12 months
</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Nil</outcome>
      <timepoint>Nil</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Adult patients with chronic tympanic membrane perforations</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>&lt; 18 years
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1 / Phase 2</phase>
    <anticipatedstartdate>3/02/2014</anticipatedstartdate>
    <actualstartdate>27/02/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>15</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
    <hospital>Fremantle Hospital and Health Service - Fremantle</hospital>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Orthocell Ltd</primarysponsorname>
    <primarysponsoraddress>Building 191 Murdoch University,
90 South St,
Murdoch,
WA 6150</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Fremantle Hospital</fundingname>
      <fundingaddress>Alma St, Fremantle, Western Australia 6160</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>University</othercollaboratortype>
      <othercollaboratorname>The University of Western Australia</othercollaboratorname>
      <othercollaboratoraddress>35 Stirling Hwy,
Crawley,
WA 6009</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>More than 106,000 Australians suffer from hearing loss and chronic ear infections related to perforations of the ear drum. Closure of these perforations traditionally requires surgery lasting up to an hour or more under general anaesthesia. Conventional myringoplasty has closure rates of ~85% in non-Indigenous populations and 50-70% in Indigenous populations. This project validates a new approach for closure of perforations requiring minimal surgery. Adults are treated under local anaesthesia with a Celgro Trademark Type I/III Collagen Bioscaffold mixed with fibrin glue placed into the perforation, thereby promoting the self-healing capacity of the eardrum. </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>South Metropolitan Health Service Human Research Ethics Committee</ethicname>
      <ethicaddress>Demountable 3, G Block,
Fremantle Hospital,
Alma St,
Fremantle,
WA 6959</ethicaddress>
      <ethicapprovaldate>15/04/2013</ethicapprovaldate>
      <hrec>12/349</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Gunesh Rajan</name>
      <address>C/o Department of Otolaryngology, Head and Neck Surgery,
Fremantle Hospital,
Alma St, 
Fremantle,
WA 6160</address>
      <phone>+61894312500</phone>
      <fax />
      <email>gunesh.rajan@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Gunesh Rajan</name>
      <address>C/o Department of Otolaryngology, Head and Neck Surgery,
Fremantle Hospital,
Alma St, 
Fremantle,
WA 6160</address>
      <phone>+61894312500</phone>
      <fax />
      <email>gunesh.rajan@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Gunesh Rajan</name>
      <address>C/o Department of Otolaryngology, Head and Neck Surgery,
Fremantle Hospital,
Alma St, 
Fremantle,
WA 6160</address>
      <phone>+61894312500</phone>
      <fax />
      <email>gunesh.rajan@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Katherine Mackie</name>
      <address>Building 191 Murdoch University,
90 South St,
Murdoch,
WA 6150</address>
      <phone />
      <fax />
      <email />
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>